Post-earnings recap
Reported
Thu, Feb 25, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Biocryst Pharmaceuticals reported a larger-than-expected loss this quarter, which contributed to a significant drop in stock price. The lack of revenue details and future guidance has raised concerns among investors. The stock's decline of 11.35% reflects market disappointment with the earnings report and uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.34 | N/A | -38.21% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns over the company's performance this quarter. They did not provide any forward guidance, indicating uncertainty.
Management did not provide specific revenue figures or guidance for the upcoming period.
The company acknowledged challenges in meeting earnings expectations.